Routine measurement of haemoglobin A1 at the diabetic outpatient clinic. by Byrne, E. et al.
ROUTINE MEASUREMENT OF HAEMOGLOBIN Al
AT THE DIABETIC OUTPATIENT CLINIC
by
E. BYRNE,' G. SAVAGE,2 J. D. MERRETT,3 L. KENNEDY,4
Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast
FOLLOWING the introduction of insulin therapy in 1922 one of the major
problems in the long-term management of insulin-dependent diabetes was the lack
of a convenient, reliable and objective test of longer term glycaemic control. In the
1960's and early 1970's haemoglobin A, (HbA,, glycosylated haemoglobin) was
shown to be elevated, usually, in diabetic patients 1-3 and its biochemical structure
was elucidated.4-6 The mid-1970's saw many reports confirming that measurement
of HbA, provided an accurate and objective assessment of glycaemic control in the
preceding 6 to 8 weeks, a period corresponding to the approximate half-life of the
average red blood cell. The vast majority of these studies were either cross-sectional
in design7-10 or, if longitudinal, carried out in the controlled atmosphere of the
clinical research centre or hospital ward.", 12
On the basis of this accumulated knowledge, measurement of HbA, has become
commonplace in many diabetic outpatient clinics. The purpose of this communi-
cation is to report how accurate measurement of HbA, has been successfully
introduced to a large diabetic outpatient clinic in such a way that the result is
available at the time of the patient's routine clinic visit. In addition, we have tried to
assess whether, in insulin-treated patients, the test yields information which is
distinct from that already available from plasma glucose measurements.
ORGANISATION OF OUTPATIENT CLINIC AND BLOOD SAMPLING
The diabetes clinics of the Royal Victoria Hospital, Belfast, are held on Tuesday
and Friday mornings of every week and, once a month, also on a Saturday morning.
Medical staff comprises at least two consultant physicians assisted by two junior
grade doctors at each clinic. In addition, a "blood sampling" clinic is held every
Wednesday morning, where patients, due to attend the following Friday, Saturday
or Tuesday, have their blood samples drawn. This suits many of the patients who
live not more than two or three miles from the hospital. Those patients who live
further away arrange to have blood samples taken on the Monday or Tuesday either
at home or at their local health clinic or general practice, and post them to the
hospital laboratory. The custom has been for some years that patients who are solely
on dietary therapy have fasting samples taken, while those on oral hypoglycaemic
agents or insulin have samples taken 2.5 hours after breakfast.
This organisational scheme was already in existence-before we introduced routine
measurement of HbA, in December 1980. We surmised that the drawing of an extra
5 ml ofblood and labelling of an extra specimen bottlewould not place an intolerable
strain on the system.
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Plasma glucose is measured by the neocuproine method. The blood samples are
put into fluoride-containing bottles.
Samples for HbA, measurement are drawn into EDTA and stored at 4°C until
Wednesday afternoon. Red cells are then incubated in normal saline at 37°C
until Thursday morning, to remove any "unstable" glycosylated fraction.'3-'7
Haemolysates are then prepared and HbA, is measured by agar gel electro-
endosmosis'8 (Corning Medical Ltd, Halsted, Essex). The normal range in our
laboratory is 3.7 to 7.2 per cent. Coefficient ofvariation within assay is 1.6 per cent
and between assays 6.4 per cent. Two standard haemolysates (high and normal
HbA,) are run each week to ensure that there is no "assay drift".
As we were concerned that postal handling or delay might affect HbAl results we
obtained duplicate samples from 21 diabetic and 5 control subjects. These were
assayed after being sent directly to the laboratory or through the post. Mean + SEM
levels were similar - 9.25 + 0.36 per cent (direct) v. 9.39 ± 0.39 per cent (postal),
and the correlation between the two sets of samples was extremely close, r = 0.94.
During the period under investigation (December 1980 to February 1982) the
laboratory were able to process approximately 110 samples for HbA, estimation
each week and have them available, with the results on computer printout sheets, for
the appropriate clinics. The maximum number of samples presented to the
laboratory in any one week was 210, and these were processed satisfactorily in the
normal way.
ASSESSMENT OF HbA, AND COMPARISON WITH PLASMA GLUCOSE
We have retrospectively identified 302 insulin-treated patients who, from
December 1st 1980 to February 28th 1981 (initial visit) had HbA, measured for the
first time under the scheme outlined as part of the routine clinic visit. Table 1 gives
details of the patient characteristics.-These patients were reviewed either twice or
three times more in the subsequent 9 to 12 months; 181 patients were reviewed at 2
to 4 months (first review), 194 at 5 to 7 months (second review) and 248 at 9 to 12
months (third review) after the initial visit. In every case there was a period of at
least 2 months between successive reviews. HbA, and plasma glucose (2.5 hour post-
breakfast) were recorded for each clinic attendance.
TABLE 1
Characteristics of302 insulin-treatedpatients
Male/Female 147/155
Duration ofdiabetes (years) - range <I to48
- median 12
Age (years) - range 7 to 83
- median 49
52To attempt to compare the information available from each of these parameters
in individual patients changes from the values at the initial visit, to subsequent
reviews, were arbitrarily defined as follows:
HbAj
- increase of > 1.5 per cent = clinically important increase
- decrease of > 1.5 per cent = clinically important decrease
- increase or decrease of < 1.5 per cent = no change
Plasma glucose
- increase of > 3 mmol/l = clinically important increase
- decrease of > 3 mmol/l = clinically important decrease
- increase or decrease of < 3 mmol/l = no change
These arbitrary values were chosen to take into account the reproducibility of the
assay methods and, in the case of plasma glucose, the likelihood of day-to-day
fluctuation.
Analysis of HbA, and plasma glucose values showed that neither of these
parameters was normally distributed within the population studied. Therefore,
comparisons were made using the Wilcoxon signedrank test for matched pairs, and
correlations using the Kendall rank correlation coefficient. The conventional level of
significance (p < 0.05) has been used in all analyses.
RESULTS
Initial visit HbA, values ranged from 5.5 to 21.0 per cent, with a
mean ± standard error of 10.7 ± 0.13 per cent. Plasma glucose ranged from 1.0 to
33.6 mmol/litre with a mean of 10.16 ± 0.35 mmol/litre. There was a weak but
statistically significant correlation between HbA, and plasma glucose - Kendall
correlation coefficient = 0.18, p < 0.001. Similar weak correlations between HbA,
and glucose were found at the first, second and third reviews, with Kendall
correlation coefficients of 0.18, 0.21 and 0.12 respectively.
TABLE 2
Comparison ofHbA, andplasma glucose at the initial visit with values at reviews
HbA, (per cent) Glucose (mmol/l)
Initial Review Initial Review
First review 10.83 ± 0.17 9.94 0.16* 10.49 ± 0.46 10.06 ± 0.50
(n = 181)
Second review 10.70± 0.15 10.13± 0.16* 10.05± 0.42 10.41 ± 0.46
(n = 197)
Third review 10.74 ± 0.14 10.74± 0.15 10.43 ± 0.38 10.55 0.39
(n = 248)
Results as mean ± SEM.
* p < 0.001, Wilcoxon signed rank test. All other differences are not statistically
significant.
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levels at the initial visit, on a paired basis, are shown in Table 2. The significant falls
in mean HbA, seen in patients at the first and second reviews were not reflected by
decreases in plasma glucose. At the third review neither ofthese parameters differed
significantly from mean levels at the initial visit.
Table 3 indicates the number of patients who had an increase, decrease, or no
change (as defined above) in HbA1 and plasma glucose at the first review compared
to the initial visit. Thus, of the 70 patients whose HbAj level decreased, plasma
glucose decreased in only 25, was unchanged in 28, and increased in 17. It can be
seen that the changes in the two parameters were concordant in only 74 of 181
patients (40.8 per cent).
TABLE 3
Comparison ofindividual "clinical changes" in HbA, andplasma glucose.
from the initial visit tofirst review
Plasma glucose
Decrease No change Increase
Decrease 25 28 17
HbA, No change 28 42 26
Increase 3 5 7
Similarly, when HbA, and plasma glucose at the second review were compared in
this fashion to levels at the initial visit, the concordance between the tests was 84 out
of 194 (43.3 per cent), and for the third review 98 out of 248 (39.5 per cent).
DISCUSSION
Apart from accurate laboratory measurement of blood or plasma glucose, assay
of HbA, is the only truly objective index of glycaemic control available to the
practising diabetologist. Other aids to assessing control, such as urine sugar testing
and home monitoring of blood glucose, are heavily dependent upon the patients'
subjective interpretation and co-operation and are, in any case, less accurate.
Saunders et al demonstrated, in 1980, that measurement of HbA, by agar gel
electroendosmosis could beperformed while patients waitedat the clinic.'9 However,
their HbA, measurements, without prior incubation of red cells in saline, would
have included the "unstable" Schiff base fraction which may be influenced by short
term fluctuations in blood glucose.'3' 17 Like them, we chose to measure HbA, by
agargel electroendosmosis. This has proven to be an accurate, reproducible method,
with many samples being processed easily by a single technician. The problem of
"unstable" HbA, has been overcome by incubating samples overnight in saline. The
apparent reliability of results from postal samples should enable our system to be
adopted by many other clinics where an extra visit to the hospital for blood sampling
is inconvenient or impractical. When, in December 1980, we started this scheme, we
confined routine HbA, measurement to insulin-treated patients as we were unsure if
the laboratory could cope with the workload. Approximately a year later we
expanded to include all patients at the clinic and the laboratory now satisfactorily
processes 180 to 200 samples each week.
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consumable materials alone cost 20 to 30 times more per test. We felt it important,
therefore, to try to assess whether these two objective tests ofglycaemic control give
distinct information, if HbA, is to be measured routinelyin patients with a condition
as common as diabetes. The retrospective analyses we have presented here show this
to be the case.
First, reductions in mean HbA, at the first and second reviews after the
introduction of the test were not reflected by changes in the mean plasma glucose
(Table 2). Secondly, the data concerning the trendofglycaemic control in individual
patients shows that, according to the criteria we laid down, conclusions drawn from
the two parameters would differ in approximately 60 per cent of cases (Table 3).
These conclusions are perhaps not unexpected bearing in mind that we are
comparing HbA, with single post-prandial plasma glucose measurements. We
believe thatsimilar conclusions would hold for fasting plasma glucose measurements
in insulin-treated patients. No doubt a greater degree of agreement would be
obtained from comparison of HbA, with the mean of several plasma glucose levels,
but we feel that our clinic is probably not unique in relying, in the majority of
patients, on a single blood sample approximately every two to four months.
Conclusions concerning the possible impact which the availability of HbAI
measurement may have on glycaemic control should not be based on a retrospective
analysis such as this. Nevertheless, speculation on why HbA, levels decreased at the
first and second reviews, but (disappointingly) increased again after 9 to 12 months,
seems reasonable. It might be argued that since the number of patients at the first
and second reviews was considerably less than at the initial visit, too much should
not be read into the decreases in HbAl. However, analysis showed no difference in
terms of age, duration of diabetes or HbAI and plasma glucose at initial visit,
between attenders and non-attenders at the first and second reviews. In any case
every patient was included in either the first or second review. It is probable,
therefore, that there was indeed an initial improvement in glycaemic control in the
cohort.
We would suggest two possible explanations for this initial but unsustained
improvement. First, enthusiasm for a "new" test on the part of the medical
personnel, with subsequent waning, could certainly account for the described
phenomenon. Interestingly, similar unsustained improvements in diabetic control
have been observed after the introduction of home blood sugar monitoring
programmes.20-22 A second possible explanation is that we were observing a seasonal
variation in glycaemic control, quite unrelated to any specific therapeutic
manoeuvre. Our study began in mid-to-late winter, with first and second reviews
largely in spring and summer, and final reviews in autumn through winter. It is easy
to believe that more intercurrent illnesses (e.g., viral) in winter and dietary excess
over the festive season would contribute to poor control, whereas increased physical
activity in the spring and summer would tend to have the opposite effect. Although a
seasonal variation in the onset of clinical diabetes is recognised,23 we are not aware
of any previous reports of seasonal variations in glycaemic control in established
diabetes.
55It is rather disappointing that approximately one year after introducing HbA,
measurement routinely at our clinic, we seem to have achieved no substantial
improvement in glycaemic control in the majority of the 302 insulin-treated patients
studied. However, we believe we have demonstrated that accurate HbAi measure-
ment can be provided with little or no disruption to established clinic routine, and
that this test yields clinically useful information not previously available.
SUMMARY
Measurement of glycosylated haemoglobin (HbAl) by agar gel electroendosmosis
was introduced as a routine test at a large teaching hospital diabetic outpatient
clinic. An initial reduction in HbA1 levels, in 302 insulin-treated patients, was not
accompanied by a corresponding decrease in post-prandial plasma glucose levels,
and was not sustained after 9 to 12 months. Changes in individual HbA, and plasma
glucose were concordant in only approximately 40 per cent of observations. The
facility ofHbAl measurement appears to give clinically distinct information, but has
not in itself led to an improvement in glycaemic control.
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